Korro Bio reports FY2025 net loss $117.3M, nominates KRRO-121 for UCD/HE; $85M PIPE extends runway to H2 2028

Korro Bio, Inc.

FY2025 net loss $117.3M vs $83.6M in FY2024, driven by $30.9M non-cash impairment charges on KRRO-110 termination.
Cash $85.2M at Dec 31, 2025; plus $85M private placement in Mar 2026 extends runway into H2 2028.
Nominated KRRO-121 for UCD and HE; regulatory filing expected H2 2026.
GalNAc AATD program achieved >90% in vivo RNA editing; candidate nomination Q2 2026.
Collaboration revenue $6.4M from Novo Nordisk (paused); R&D expenses $65.6M, G&A $28.2M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Korro Bio, Inc. reported the fiscal year ended December 31, 2025 results: revenue $6.4 million.

Period: the fiscal year ended December 31, 2025
Revenue: $6.4 million
Result: reported results

Exact text from the filing

There was $6.4 million of collaboration revenue for the year ended December 31, 2025, as compared to $2.3 million for the year ended December 31, 2024.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Korro Bio, Inc. reported financial results for the fourth quarter ended December 31, 2025.

Period: the fourth quarter ended December 31, 2025
Result: reported results

Exact text from the filing

Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company developing a new class of genetic medicines based on RNA editing for rare and highly prevalent diseases, today reported results for the fourth quarter and full year ended on December 31, 2025, and provided a corporate update.

View on SEC.gov

1 earnings releases filed in the last 30 days. Browse all earnings releases →

Korro Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-104135

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.